A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model.

Anna Pons-Grifols,Ferran Tarres-Freixas,Mónica Pérez,Eva Riveira-Muñoz,Dalia Raich-Regué,Daniel Perez-Zsolt,Jordana Muñoz-Basagoiti,Barbara Tondelli,Nuria Izquierdo-Useros,Sara Capdevila,Julia Vergara-Alert,Víctor Urrea,Jorge Carrillo,Ester Ballana,Stephen Forrow,Bonaventura Clotet,Joaquim Segales,Benjamin Trinite,Julia Blanco

DOI: https://doi.org/10.1101/2024.06.11.598471

2024-06-13

Abstract:Animal models have been instrumental in elucidating the pathogenesis of SARS-CoV-2 infection and testing COVID-19 vaccines and therapeutics. Wild-type (WT) mice are not susceptible to many SARS-CoV-2 variants, therefore transgenic K18-hACE2 mice have emerged as a standard model system. However, this model is characterized by severe disease, particularly associated with neuroinfection, which leads to early humane endpoint euthanasia. Here, we established a novel knock-in (KI) mouse model by inserting the original K18-hACE2 transgene into the collagen COL1A1 locus using a recombinase mediated cassette exchange (RMCE) system. Once the Col1a1-K18-hACE2 mouse colony was established, animals were challenged with a B.1 SARS-CoV-2 (D614G) isolate and were monitored for up to 14 days. Col1a1-K18-hACE2 mice exhibited an initial weight loss similar to the K18-hACE2 transgenic model but did not develop evident neurologic clinical signs. The majority of Col1a1-K18-hACE2 mice did not reach the preestablished humane endpoint, showing progressive weight gain after 9 days post-infection (dpi). Importantly, despite this apparent milder pathogenicity compared to the K18-hACE2 transgenic model, high levels of viral RNA were detected in lungs, oropharyngeal swab, and nasal turbinate. Conversely, in sharp contrast to K18-hACE2 transgenic mice, no viral replication was detected in the brains of Col1a1-K18-hACE2 animals at any timepoint, explaining the reduced severity of clinical signs. At 14 dpi, while infection was cleared in the lungs, increased lesions and residual inflammation were detected. Overall, Col1a1-K18-hACE2 mice constitute a new model for investigating SARS-CoV-2 pathogenesis and treatments, with potential implications for studying long-term COVID-19 sequelae.

Microbiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a new animal model to more accurately simulate the pathological process of SARS - CoV - 2 infection in the human body, especially to avoid the serious neurological disease problems existing in the existing K18 - hACE2 transgenic mouse model. Specifically, the researchers created a new knock - in (KI) mouse model - Col1a1 - K18 - hACE2 by inserting the human ACE2 gene (hACE2) into the collagen COL1A1 locus in mice in a site - specific manner. This new model aims to overcome the problem of early humane endpoint euthanasia in the K18 - hACE2 transgenic mouse model due to viral neuroinvasion, thereby providing an animal model more suitable for studying long - term COVID - 19 sequelae, disease - specific aspects, and reinfection susceptibility after SARS - CoV - 2 infection.

The key objectives of the paper include:
1. **Evaluating the infectivity of the new model**: Verifying whether Col1a1 - K18 - hACE2 mice can be effectively infected by the SARS - CoV - 2 B.1 (D614G) variant.
2. **Comparing pathological features**: Compared with K18 - hACE2 transgenic mice, evaluating the differences in clinical manifestations, body weight changes, viral load, histopathological changes, and inflammatory responses in Col1a1 - K18 - hACE2 mice after infection.
3. **Exploring neuroinvasion**: Paying special attention to whether Col1a1 - K18 - hACE2 mice will have brain virus infections and related lesions, which is a major problem observed in the K18 - hACE2 model.

Through these studies, the authors hope to provide an animal model that is more in line with the characteristics of human SARS - CoV - 2 infection, in order to better understand the mechanism of the disease and provide support for the research and development of vaccines and therapeutic drugs.